0.171
Vivosim Labs Inc Aktie (VIVS) Neueste Nachrichten
Press Releases about Volato Group, Inc. Class A Common Stock (NYSE:SOAR) - FinancialContent
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials - Carroll County Mirror-Democrat
Received 5M from Eli Lilly - Moomoo
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - openPR.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - WBOC TV
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - marketscreener.com
VivoSim Labs (VIVS) CCO buys 10,000 shares outside trading plan - Stock Titan
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - FinancialContent
VivoSim plans rat liver model to complement human testing - Investing.com
VivoSim Labs to Add Rat Liver Model to NAMkind Platform - Yahoo Finance UK
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - Barchart.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
Big Pharma giant Eli Lilly pays $6M to VivoSim Labs 🤯🔥 $Xiao-I (AIXI.US)$ $CID Holdco (DAIC.US)$ - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - openPR.com
VivoSim Labs (VIVS) News Flow - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
The Largest Pharma On The Planet Sent Cash to a Micro cap 👀 - Moomoo
VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VivoSim Labs, INC. SEC Filing (Aug 21, 2026) - Stock Titan
Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10% - Stock Titan
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - WBOC TV
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - FinancialContent
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as - openPR.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus - FinancialContent
VivoSim Labs (VIVS) seeks approval for reverse split, equity plan and warrant repricing - Stock Titan
VivoSim: Fiscal Q1 Earnings Snapshot - marketscreener.com
VivoSim: Fiscal Q1 Earnings Snapshot - KTVB
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside - FinancialContent
$VIVS Load up 🔥🚀 - Moomoo
VivoSim Labs, INC. SEC Filing (Aug 11, 2026) - Stock Titan
VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance - Stock Titan
VivoSim Labs (VIVS) Revenue BreakdownMain Composition - Moomoo
VivoSim Labs (VIVS) News Flow - Moomoo
VIVS PE Ratio & Valuation, Is VIVS Overvalued - Intellectia AI
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Moomoo
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com UK
VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 - Minichart
VivoSim Labs regains Nasdaq compliance after cash infusion - Investing.com
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com Nigeria
🍋💦🍋💦💣🚀 - Moomoo
VivoSim Provides Financial and Listing Compliance Update - The Manila Times
VivoSim regains Nasdaq compliance after $10.1 million cash update - Quiver Quantitative
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):